Trial reportJournal of clinical microbiology2006
Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.
Trial report in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 103 citations in OpenAlex.
- Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships.Open forum infectious diseases · 2019Article
- HCV Detection, Discrimination, and Genotyping Technologies.Sensors (Basel, Switzerland) · 2018Review
- Prevalence of Diabetes Type 2 in Hepatitis C Infected Patients in Kpk, Pakistan.BioMed research international · 2017Article
- Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response.Scientific reports · 2016Article
- Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.Medical microbiology and immunology · 2015Article
- Direct quantitative analysis of HCV RNA by atomic force microscopy without labeling or amplification.Nucleic acids research · 2012Article
- Genotype 3 diversity and quantification of hepatitis E virus RNA.Journal of clinical microbiology · 2012Article
- Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains.PloS one · 2012Article
- HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate.PloS one · 2012Article
- Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.Journal of clinical microbiology · 2011Article
- Detection of hepatitis C virus by an improved loop-mediated isothermal amplification assay.Archives of virology · 2011Article
- A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control.Virology journal · 2010Article
- Hepatitis C virus RNA quantitation in venous and capillary small-volume whole-blood samples.Journal of clinical microbiology · 2009Article
- Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay.Journal of clinical microbiology · 2009Article
- A novel diagnostic target in the hepatitis C virus genome.PLoS medicine · 2009Article
- Expert opinion on the treatment of patients with chronic hepatitis C.Journal of viral hepatitis · 2009Review
- Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection.Journal of clinical microbiology · 2008Article
- Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification.Journal of clinical microbiology · 2008Article
- Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.The Journal of molecular diagnostics : JMD · 2008Article
- Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study.Journal of clinical microbiology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key parameter for diagnosis and management of hepatitis C virus (HCV) infection is HCV RNA. Standardization of HCV RNA assays to IU is mainly based on genotype 1 panels. Little is known about the variability of commercially available HCV RNA assays for quantification of different genotypes. Two real-time reverse transcription (RT)-PCR assays (COBAS TaqMan HCV Test for use with the High-Pure System [HPS/CTM] and COBAS Ampliprep/COBAS TaqMan HCV Test [CAP/CTM]), one standard RT-PCR assay (COBAS Amplicor HCV Monitor 2.0 [CAM]), and one signal amplification assay (Versant Quantitative 3.0 [branched DNA [bDNA]]) were compared for quantification of genotypes 1 to 5 (n = 108). Using CAM as a reference assay for genotype 1-infected patients, the mean interassay differences compared with CAP/CTM, HPS/CTM, and bDNA were 0.16, -0.13, and -0.48 log(10) IU/ml HCV RNA, respectively. Comparison of CAM with CAP/CTM, HPS/CTM, and bDNA for the remaining genotypes showed the following results, respectively: 2a/c, -0.24, -0.78, and -0.49; 2b, -0.21, -0.18, and -0.64; 3a, 0.13, -1.04, and -0.55; 4, -0.52, -1.51, and -0.05; and 5, -0.28, -1.00, and -0.24 log IU/ml HCV RNA. A correct decision for treatment discontinuation in genotype 1 patients at week 12 was possible only when the same assay was used at baseline and week 12. Comparison of CAM with the CAP/CTM assay showed equal quantifications of genotype 1, 2, 3, and 5 samples, while genotype 4 samples were slightly underestimated. For the HPS/CTM assay, a significant underestimation of the HCV RNA concentrations of genotypes 2a/c, 3, 4, and 5 was observed. For the bDNA assay, a constant lower quantification of genotypes 1 to 3 was detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.